PBLA
Price
$1.13
Change
+$0.02 (+1.80%)
Updated
Feb 23, 3:02 PM EST
SPRO
Price
$1.51
Change
+$0.04 (+2.72%)
Updated
Feb 23, 3:11 PM EST
19 days until earnings call
Ad is loading...

PBLA vs SPRO ᐉ Comparison: Which is Better to Invest?

Header iconPBLA vs SPRO Comparison
Open Charts PBLA vs SPROBanner chart's image
Panbela Therapeutics
Price$1.13
Change+$0.02 (+1.80%)
Volume$240
CapitalizationN/A
Spero Therapeutics
Price$1.51
Change+$0.04 (+2.72%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
PBLA vs SPRO Comparison Chart

Loading...

PBLADaily Signal changed days agoGain/Loss if shorted
 
Show more...
SPRODaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
PBLA vs. SPRO commentary
Feb 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBLA is a Hold and SPRO is a StrongSell.

COMPARISON
Comparison
Feb 23, 2024
Stock price -- (PBLA: $1.10 vs. SPRO: $1.47)
Brand notoriety: PBLA and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBLA: 33% vs. SPRO: 112%
Market capitalization -- PBLA: $3.83M vs. SPRO: $77.91M
PBLA [@Biotechnology] is valued at $3.83M. SPRO’s [@Biotechnology] market capitalization is $77.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $538.15B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBLA’s FA Score shows that 1 FA rating(s) are green whileSPRO’s FA Score has 0 green FA rating(s).

  • PBLA’s FA Score: 1 green, 4 red.
  • SPRO’s FA Score: 0 green, 5 red.
According to our system of comparison, SPRO is a better buy in the long-term than PBLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBLA’s TA Score shows that 3 TA indicator(s) are bullish while SPRO’s TA Score has 6 bullish TA indicator(s).

  • PBLA’s TA Score: 3 bullish, 3 bearish.
  • SPRO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SPRO is a better buy in the short-term than PBLA.

Price Growth

PBLA (@Biotechnology) experienced а -13.31% price change this week, while SPRO (@Biotechnology) price change was -3.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.34%. For the same industry, the average monthly price growth was +19.68%, and the average quarterly price growth was +40.54%.

Reported Earning Dates

PBLA is expected to report earnings on May 16, 2023.

SPRO is expected to report earnings on May 09, 2024.

Industries' Descriptions

@Biotechnology (+3.34% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for PBLA with price predictions.
OPEN
A.I.dvisor published
a Summary for SPRO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SPRO($77.9M) has a higher market cap than PBLA($3.83M). SPRO has higher P/E ratio than PBLA: SPRO (3.77) vs PBLA (0.00). SPRO YTD gains are higher at: 0.000 vs. PBLA (-93.984). SPRO has higher annual earnings (EBITDA): 1.06M vs. PBLA (-23.28M). SPRO has more cash in the bank: 93.8M vs. PBLA (907K). PBLA has less debt than SPRO: PBLA (5.19M) vs SPRO (5.83M). SPRO has higher revenues than PBLA: SPRO (76.2M) vs PBLA (0).
PBLASPROPBLA / SPRO
Capitalization3.83M77.9M5%
EBITDA-23.28M1.06M-2,206%
Gain YTD-93.9840.000-
P/E Ratio0.003.770%
Revenue076.2M-
Total Cash907K93.8M1%
Total Debt5.19M5.83M89%
FUNDAMENTALS RATINGS
PBLA vs SPRO: Fundamental Ratings
PBLA
SPRO
OUTLOOK RATING
1..100
839
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
9848
P/E GROWTH RATING
1..100
9592
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBLA's Valuation (11) in the null industry is in the same range as SPRO (36) in the Pharmaceuticals Major industry. This means that PBLA’s stock grew similarly to SPRO’s over the last 12 months.

PBLA's Profit vs Risk Rating (100) in the null industry is in the same range as SPRO (100) in the Pharmaceuticals Major industry. This means that PBLA’s stock grew similarly to SPRO’s over the last 12 months.

SPRO's SMR Rating (90) in the Pharmaceuticals Major industry is in the same range as PBLA (100) in the null industry. This means that SPRO’s stock grew similarly to PBLA’s over the last 12 months.

SPRO's Price Growth Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for PBLA (98) in the null industry. This means that SPRO’s stock grew somewhat faster than PBLA’s over the last 12 months.

SPRO's P/E Growth Rating (92) in the Pharmaceuticals Major industry is in the same range as PBLA (95) in the null industry. This means that SPRO’s stock grew similarly to PBLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBLASPRO
RSI
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
PBLADaily Signal changed days agoGain/Loss if shorted
 
Show more...
SPRODaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNDY207.60-0.38
-0.18%
monday.com Ltd
LUXH2.84-0.05
-1.73%
LuxUrban Hotels
AY18.36-0.57
-3.01%
Atlantica Sustainable Infrastructure plc
NNOX8.89-0.35
-3.80%
NANO-X IMAGING Ltd
NVVE0.84-0.04
-4.86%
Nuvve Holding Corp

PBLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBLA has been closely correlated with VSTM. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if PBLA jumps, then VSTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBLA
1D Price
Change %
PBLA100%
-4.26%
VSTM - PBLA
77%
Closely correlated
-2.43%
APLMW - PBLA
35%
Loosely correlated
+9.04%
XOMAP - PBLA
32%
Poorly correlated
+0.48%
CLNN - PBLA
28%
Poorly correlated
-4.38%
IVVD - PBLA
27%
Poorly correlated
+1.25%
More

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with HRTX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then HRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
-2.65%
HRTX - SPRO
38%
Loosely correlated
-4.73%
CTMX - SPRO
37%
Loosely correlated
+2.07%
OCUL - SPRO
37%
Loosely correlated
+28.92%
IMAB - SPRO
37%
Loosely correlated
-1.25%
XNCR - SPRO
36%
Loosely correlated
+1.20%
More